Citation: V. Grill et al., Humoral hypercalcemia of malignancy: The discovery of PTHrP, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 21-40
Authors:
Yoneda, T
Williams, PJ
Myoi, A
Michigami, T
Mbalaviele, G
Citation: T. Yoneda et al., Cellular and molecular mechanisms of development of skeletal metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 41-69
Citation: D. Goltzman et Sa. Rabbani, Pathogenesis of osteoblastic metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 71-84
Citation: M. Pecherstorfer et M. Vesely, Diagnosis and monitoring of bone metastases: Clinical means, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 97-129
Citation: Gjr. Cook et I. Fogelman, Diagnosis and monitoring of bone metastases: Scintigraphy, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 131-154
Citation: M. Parsa et Md. Murphey, Radiographic diagnosis and monitoring of bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 155-195
Citation: J. Hilkens et H. Bonfrer, Diagnosis and monitoring of bone metastases: Serum tumor markers, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 197-212
Citation: A. Fontana et al., Markers of bone turnover in diagnosis and monitoring of bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 213-226
Citation: Rl. Theriault et Gn. Hortobagyi, Treatment of bone metastases: Chemo- and hormone therapy, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 227-243
Authors:
Preston, DF
Baxter, KG
Schiefelbein, M
Spicer, JA
Citation: Df. Preston et al., Palliation of painful bone metastases: Radioactive isotopes, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 287-304
Citation: Ha. Fleisch, Bisphosphonates: Introduction and mechanisms of action in tumor prevention, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 357-376
Citation: Re. Coleman, Treatment of tumor-induced osteolysis and prevention of skeletal-related events in patients with bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 409-434
Citation: Ahg. Paterson, Prospects of bisphosphonates: for the prevention of bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 435-455
Citation: Ja. Kanis et Ev. Mccloskey, Bisphosphonates in the treatment of multiple myeloma, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 457-481
Citation: B. Winding et al., Osteoporosis in patients with a history of breast cancer: Causes and diagnosis, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 493-514
Citation: Ki. Pritchard, Osteoporosis in patients with a history of breast cancer treated with estrogen-replacement therapy, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 515-537
Citation: D. Thiebaud et P. Burckhardt, Osteoporosis in patients with a history of breast cancer: Bisphosphonates and other drugs, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 539-554